SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.22+1.6%Jan 13 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (9707)12/10/2003 3:18:51 PM
From: Sam Citron  Read Replies (2) of 52153
 
Note the FluMist plug...Dr. Robert Belshe of St. Louis University said FluMist was tested in children during the season when A-Sydney emerged, and it still appeared to be 86 percent protective. More than 90 percent of children given FluMist that year made antibodies against the new strain, compared with less than a third who received standard flu shots.

Is this a "plug", a fact, or a fiction? Does it support the premise that "FluMist nasal spray vaccine, which uses a weakened live virus, may do a better job of protecting against a mismatched virus" such as the genetic mutations in A-Fujian? Do you have any reason to believe that Belshe might have an undisclosed bias, such as a relationship with Medimmune? Do you have any such bias?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News